DCTH - Delcath Systems, Inc. Stock Price, Fair Value and News

$9.64+0.33 (+3.54%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DCTH Price Action

Last 30 days

1.3%

Last 90 days

-13.1%

Trailing 12 Months

-18.7%

DCTH RSI Chart

DCTH Valuation

Market Cap

340.4M

Price/Earnings (Trailing)

284.16

Price/Sales (Trailing)

4.28

EV/EBITDA

38.43

Price/Free Cashflow

28.33

DCTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DCTH Fundamentals

DCTH Revenue

Revenue (TTM)

79.6M

Rev. Growth (Yr)

83.6%

Rev. Growth (Qtr)

-14.87%

DCTH Earnings

Earnings (TTM)

1.2M

Earnings Growth (Yr)

-55.47%

Earnings Growth (Qtr)

-69.23%

DCTH Profitability

Operating Margin

86.29%

EBT Margin

8.43%

Return on Equity

1.04%

Return on Assets

0.96%

Free Cashflow Yield

3.53%

DCTH Investor Care

Shares Dilution (1Y)

10.45%

Diluted EPS (TTM)

0.05

DCTH Alerts

2 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	53.9M	70.2M	79.6M	0
2024	4.6M	11.9M	22.6M	37.2M
2023	2.9M	2.6M	2.2M	2.1M
2022	3.2M	3.2M	3.3M	2.7M
2021	0	0	0	3.6M
2018	2.7M	2.9M	3.1M	0
2017	2.4M	2.4M	2.7M	2.7M
2016	1.7M	1.7M	1.8M	2.0M
2015	1.2M	1.4M	1.6M	1.7M
2014	720.0K	971.0K	1.1M	1.1M
2013	457.3K	568.5K	679.8K	791.0K
2012	0	0	0	346.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

CEO	Mr. Gerard J. Michel MBA, MS
WEBSITE	delcath.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	52

Delcath Systems, Inc. Frequently Asked Questions

What is the ticker symbol for Delcath Systems, Inc.? What does DCTH stand for in stocks?

DCTH is the stock ticker symbol of Delcath Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Delcath Systems, Inc. (DCTH)?

As of Wed Dec 03 2025, market cap of Delcath Systems, Inc. is 340.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DCTH stock?

You can check DCTH's fair value in chart for subscribers.

Is Delcath Systems, Inc. a good stock to buy?

The fair value guage provides a quick view whether DCTH is over valued or under valued. Whether Delcath Systems, Inc. is cheap or expensive depends on the assumptions which impact Delcath Systems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DCTH.

What is Delcath Systems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, DCTH's PE ratio (Price to Earnings) is 284.16 and Price to Sales (PS) ratio is 4.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCTH PE ratio will change depending on the future growth rate expectations of investors.